biomerica.png
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
April 26, 2022 08:19 ET | Biomerica, Inc.
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major...
biomerica.png
Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™
June 24, 2021 08:19 ET | Biomerica, Inc.
Prevalence of H. pylori infection in the United States is approximately 35% to 40% of the population IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced...
red.jpg
RedHill Biopharma Increases Patient Access to Talicia® with EnvisionRx Formularies
July 27, 2020 07:00 ET | RedHill Biopharma Ltd.
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori to...
red.jpg
RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults
November 04, 2019 06:05 ET | RedHill Biopharma Ltd.
RedHill plans to launch Talicia®1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for H. pylori infection...
red.jpg
RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
May 07, 2019 06:05 ET | RedHill Biopharma Ltd.
The NDA follows a recent positive pre-NDA meeting with the FDA The NDA for Talicia® is eligible for six-month priority review Talicia® is eligible for a total of eight years of U.S. market...
red.jpg
RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection
December 03, 2018 07:01 ET | RedHill Biopharma Ltd.
The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance (p<0.0001) High resistance to...
red.jpg
RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection
September 04, 2018 07:00 ET | RedHill Biopharma Ltd.
Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA® are expected before year’s end    The ERADICATE Hp2 study enrolled 455 patients with...
red.jpg
RedHill Biopharma Enrolls 400th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
July 24, 2018 08:22 ET | RedHill Biopharma Ltd.
400 of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA® for H. pylori infection (ERADICATE Hp2)RedHill expects to complete enrollment...
red.jpg
RedHill Biopharma Announces Standard-of-Care Eradication Data From the RHB-105 Phase III Study Further Supporting the Study's Positive Results
September 08, 2015 09:00 ET | RedHill Biopharma Ltd.
Patients enrolled in the placebo arm of the ERADICATE Hp Phase III study received open-label standard-of-care (SoC) therapy for persistent Helicobacter pylori (H. pylori) infection; results from...
red.jpg
RedHill Biopharma to Host First Quarter 2015 Financial Results Conference Call on April 30, 2015
April 21, 2015 07:00 ET | RedHill Biopharma Ltd.
TEL-AVIV, Israel, April 21, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...